10 Actavis plc Analyst Ratings, Earnings, Dividends and Insider Trades | $ACT | NYSE:ACT | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Actavis plc Company Profile (NYSE:ACT) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Actavis plc (NYSE:ACT) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 5 Hold Rating(s), 14 Buy Rating(s)Consensus Rating:Buy (Score: 2.74)Consensus Price Target: $193.18 7.43% downside) Analysts' Ratings History for Actavis plc (NYSE:ACT) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/25/2014ArgusBoost Price Target$198.00 -> $225.00View 2/21/2014RBC CapitalBoost Price TargetOutperform$240.00 -> $249.00View 2/19/2014BarclaysBoost Price TargetOverweight$230.00 -> $250.00View 2/19/2014UBS AGBoost Price TargetBuy$202.00 -> $237.00View 2/19/2014MizuhoDowngradeBuy -> Neutral$93.00 -> $25.00View 2/19/2014CRT CapitalBoost Price TargetBuy$210.00 -> $230.00View 2/19/2014Bank of AmericaSet Price TargetBuy$200.00 -> $235.00View 2/19/2014Buckingham ResearchBoost Price Target$210.00 -> $250.00View 2/19/2014Goldman SachsUpgradeNeutral -> Buy$185.00 -> $250.00View 2/4/2014ZacksUpgradeNeutral -> Outperform$224.00View 2/3/2014Morgan StanleyBoost Price Target$182.00 -> $205.00View 2/3/2014RBC CapitalBoost Price TargetOutperform$202.00 -> $222.00View 2/3/2014BarclaysBoost Price TargetOverweight$190.00 -> $230.00View 2/3/2014JPMorgan Chase & Co.Boost Price Target$215.00 -> $230.00View 1/28/2014Piper JaffrayBoost Price TargetOverweight$175.00 -> $203.00View 1/17/2014ArgusBoost Price TargetBuy$180.00 -> $198.00View 1/10/2014Cowen and CompanyUpgradeMarket Perform -> Outperform$130.00 -> $215.00View 1/7/2014RBC CapitalInitiated CoverageOutperform$202.00View 11/28/2013ZacksDowngradeOutperform -> Neutral$172.00View 10/30/2013UBS AGBoost Price TargetBuy$155.00 -> $186.00View 10/30/2013SusquehannaBoost Price TargetNeutral$165.00 -> $170.00View 10/30/2013JPMorgan Chase & Co.Boost Price TargetOverweight$160.00 -> $170.00View 10/30/2013ZacksReiterated RatingOutperform -> Outperform$185.00View 10/30/2013Jefferies GroupBoost Price TargetIn-Line -> Hold$133.00 -> $168.00View 10/30/2013BarclaysSet Price TargetOverweight$175.00 -> $190.00View 10/30/2013TheStreetDowngradeBuy -> HoldView 10/25/2013Citigroup Inc.Initiated CoverageBuy$172.00View 10/22/2013TheStreetDowngradeBuy -> HoldView 10/21/2013SusquehannaBoost Price TargetNeutral$140.00 -> $165.00View 10/14/2013TheStreetDowngradeBuy -> HoldView 10/7/2013ZacksUpgradeNeutral -> Outperform$176.00View 10/3/2013TheStreetDowngradeBuy -> HoldView 10/1/2013ArgusReiterated RatingBuy$150.00View 10/1/2013Leerink SwannBoost Price Target$165.00View 9/25/2013ZacksReiterated RatingNeutral -> Neutral$146.00View 9/16/2013ArgusReiterated RatingBuy$150.00View 9/16/2013BarclaysBoost Price TargetOverweight$140.00 -> $175.00View 8/14/2013JPMorgan Chase & Co.Boost Price TargetOverweight$150.00 -> $160.00View 7/30/2013ArgusBoost Price TargetBuy$120.00 -> $150.00View 7/29/2013Leerink SwannUpgradeMarket Perform -> Outperform$155.00View 7/26/2013CRT CapitalBoost Price TargetBuy$140.00 -> $150.00View 7/22/2013ZacksReiterated RatingNeutral -> Neutral$132.00View 5/30/2013UBS AGBoost Price TargetBuy$120.00 -> $155.00View 5/30/2013RBC CapitalBoost Price TargetOutperform$108.00 -> $136.00View 5/21/2013JPMorgan Chase & Co.Boost Price TargetOverweight$115.00 -> $150.00View 5/21/2013GuggenheimBoost Price TargetBuy$125.00 -> $148.00View 5/21/2013BMO Capital MarketsBoost Price TargetOutperform$124.00 -> $145.00View 5/21/2013Piper JaffrayReiterated RatingOverweight$128.00 -> $160.00View 5/21/2013BarclaysBoost Price TargetOverweight$120.00 -> $140.00View 5/20/2013Morgan StanleyBoost Price Target$140.00View 5/16/2013Jefferies GroupReiterated RatingHold$120.00 -> $133.00View 5/15/2013Canaccord GenuityBoost Price TargetBuy$115.00 -> $136.00View 5/9/2013BMO Capital MarketsInitiated CoverageOutperformView 5/6/2013RBC CapitalBoost Price TargetOutperform$100.00 -> $108.00View 5/3/2013ArgusBoost Price TargetBuy$100.00 -> $120.00View 5/3/2013ZacksReiterated RatingNeutral -> Neutral$112.00View 5/3/2013BarclaysBoost Price TargetOverweight$110.00 -> $120.00View 5/3/2013UBS AGBoost Price TargetBuy$103.00 -> $120.00View 5/3/2013Sanford C. BernsteinSet Price TargetOutperform$105.00 -> $118.00View 5/3/2013SusquehannaDowngradePositive -> NeutralView 4/29/2013Canaccord GenuityBoost Price TargetBuy$102.00 -> $115.00View 4/29/2013Piper JaffrayBoost Price TargetOverweight$103.00 -> $120.00View 4/11/2013ZacksReiterated RatingNeutral -> Neutral$102.00View 4/3/2013TheStreetUpgradeHold -> BuyView 4/2/2013Canaccord GenuityBoost Price TargetBuy$102.00View 4/2/2013Morgan StanleyBoost Price TargetOverweight$101.00View 3/21/2013JPMorgan Chase & Co.Boost Price TargetOverweight$100.00 -> $102.00View 3/19/2013Goldman SachsReiterated RatingNeutral$94.00 -> $95.00View 3/18/2013Wells Fargo & Co.DowngradeOutperform -> Market PerformView 3/14/2013TheStreetDowngradeHoldView 3/12/2013Morgan StanleyReiterated RatingOverweightView 2/20/2013Sanford C. BernsteinReiterated RatingOutperform$99.00View 2/19/2013Cowen and CompanyDowngradeOutperform -> NeutralView 2/15/2013Jefferies GroupReiterated RatingHold$81.00View 1/29/2013RBC CapitalLower Price TargetOutperform$97.00 -> $95.00View 1/28/2013Goldman SachsLower Price TargetNeutral$96.00 -> $94.00View 1/28/2013SusquehannaReiterated RatingPositive$101.00View 1/25/2013Morgan StanleyInitiated CoverageOverweight$98.00View (Data available from 3/11/2012 forward) Earnings History for Actavis plc (NYSE:ACT)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView 10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView 7/25/2013Q2 2013$2.00$2.01$1.99 billion$1.99 billionViewListenView 5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView 2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView (Data available from 1/1/2011 forward) Dividend History for Actavis plc (NYSE:ACT)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Actavis plc (NYSE:ACT)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.00View 9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View 9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View 8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.00View 8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.00View 8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00View 8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.64View 8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.00View 8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00View 8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.01View 8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.00View 8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.00View 8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.00View 8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.00View 8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.28View 3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View 3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View (Data available from 1/1/2013 forward) About Actavis plc Actavis, Inc. formerly Watson Pharmaceuticals, Inc., is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd. Headlines: (2/18) Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction (2/18) Actavis to buy Forest for $25 billion; windfall for investor Icahn (2/18) Actavis to Buy Forest Laboratories for $25 Billion (2/18) Fitch Affirms Actavis at 'BBB-' on Forest Labs Acquisition; Outlook Stable (2/17) Actavis in talks to buy Forest Labs for as much as $25 billion - WSJ (2/17) Actavis Said to Near $25 Billion Deal to Buy Forest Labs (2/28) Actavis Confirms Generic Multaq® Patent Challenge (2/28) Actavis Confirms Generic Colcrys® Patent Challenge Industry, Sector and Symbol: Sector: Healthcare Industry: Pharmaceuticals Sub-Industry: Pharmaceuticals Exchange: NYSE Symbol: ACT CUSIP: 00507K10 Key Metrics: Previous Close: $213.1850 Day Moving Average: $200.15200 Day Moving Average: $165.277 P/E Ratio: N/AP/E Growth: 0.92Market Cap: $36.206BCurrent Quarter EPS Consensus Estimate: $13.03 EPS Additional Links: View ACT on Google FinanceView ACT on Yahoo FinanceView ACT's Company Profile on ReutersSearch for Actavis plc on Google Actavis plc (NYSE:ACT) Chart for Tuesday, March, 11, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.